Clinical Trial Results TV
EVEREST: Effects of Vasopressin Receptor Antagonism With Tolvaptan on Clinical Status, Morbidity, and Mortality in Patie
EVEREST: Effects of Vasopressin Receptor Antagonism With Tolvaptan on Clinical Status,
Morbidity, and Mortality in Patients Hospitalized With Acute Decompensated Heart Failure
by Marvin Konstam, MD

Sponsorship for the booth and interviews at ACC 2007 was provided by the Center for Health
Education (CHE) through unrestricted joint educational grants from the Medicines Company,
Merck, Schering-Plough and Scios.

[ Download video ]


Video Statistics
4 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 1 total votes.

These statistics are updated nightly. The last update ran on
11-22-2017 EST at 1 am.

Additional Files
Filename File Description Action
251.ppt EVEREST Slides Download

Comments [ login to comment ]
No comments have been submitted